E Fund Management Co. Ltd. Has $551,000 Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

E Fund Management Co. Ltd. trimmed its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 15.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 6,318 shares of the biotechnology company’s stock after selling 1,190 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Blueprint Medicines were worth $551,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of BPMC. Quarry LP bought a new stake in shares of Blueprint Medicines during the 3rd quarter valued at $32,000. R Squared Ltd bought a new stake in shares of Blueprint Medicines during the 4th quarter valued at $51,000. Covestor Ltd lifted its position in shares of Blueprint Medicines by 206.7% during the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 403 shares during the period. Asset Management One Co. Ltd. bought a new stake in shares of Blueprint Medicines during the 4th quarter valued at $88,000. Finally, Van ECK Associates Corp lifted its position in shares of Blueprint Medicines by 48.2% during the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 363 shares during the period.

Blueprint Medicines Price Performance

Shares of BPMC opened at $87.12 on Friday. Blueprint Medicines Co. has a 1 year low of $80.68 and a 1 year high of $121.90. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The company has a market capitalization of $5.57 billion, a price-to-earnings ratio of -80.67 and a beta of 0.62. The business has a 50-day moving average of $99.43 and a 200-day moving average of $94.27.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, equities research analysts anticipate that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Ariel Hurley sold 1,819 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94. Following the completion of the sale, the insider now owns 14,967 shares in the company, valued at $1,395,822.42. The trade was a 10.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jeffrey W. Albers sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $89.77, for a total value of $1,346,550.00. Following the sale, the director now owns 157,557 shares of the company’s stock, valued at approximately $14,143,891.89. This represents a 8.69 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 48,427 shares of company stock worth $4,837,801. 4.21% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Stephens reiterated an “overweight” rating and set a $140.00 target price on shares of Blueprint Medicines in a research report on Thursday, January 2nd. JPMorgan Chase & Co. upped their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. HC Wainwright restated a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. Wedbush restated an “outperform” rating and set a $128.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 28th. Finally, JMP Securities restated a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Blueprint Medicines currently has a consensus rating of “Moderate Buy” and an average price target of $125.21.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.